62 filings
Page 2 of 4
8-K
yv1 pwkamkyg
24 Feb 23
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
5:25pm
8-K
jpl1wr i7unl
13 Feb 23
Other Events
5:34pm
8-K
4899rq226l54enxtz
13 Feb 23
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
7:08am
8-K
rklhff02pqzm rsnn6f
10 Feb 23
Other Events
4:31pm
8-K
cjdqpuznuizz
30 Jan 23
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
4:45pm
8-K
f3c3kdv2gdjp9i1df
26 Jan 23
Other Events
8:00am
8-K
xr3n9
9 Jan 23
Other Events
8:00am
8-K
9zuvxni cti3uc95lw1
17 Nov 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
kvgto
16 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:29pm
8-K
fwqh4 d1b4lnps28t1e
9 Nov 22
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
4:23pm
8-K
j5e2bijunb7btu73
16 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
f34ir17g
19 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
sgxpef qf
11 Aug 22
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
4:26pm
8-K
77blp0x6ukf2673gu70
2 Aug 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
z0oigdffz fj
29 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
2i83isjrrmfahdmdey0
1 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:04pm
8-K
gqxba5
16 May 22
Entry into a Material Definitive Agreement
9:28pm
8-K
1uebm
16 May 22
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
9:33am
8-K
wrl85uz 6g9
15 Mar 22
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
4:23pm
8-K
i9x5 br4ifsu
13 Jan 22
J.P. Morgan 40 th Annual Healthcare Conference January 2022
8:00am